< Back

May, 2019

340B is a Growing Business Line for SPs - Vital, Uncertain, and Fraught with Potential Misuse and Exploitation

Specialty Pharmacies and Specialty Distributors | May 2019

340B is a Growing Business Line for SPs - Vital, Uncertain, and Fraught with Potential Misuse and Exploitation

Volume and Growth in 340B

Download Complimentary Research Slide

Key questions:

  • What are the key changes to 340B reimbursement methodologies and covered-entity qualifications that will impact SPs most directly?
  • How will the leading SPs respond strategically and tactically to these changes?
  • What will be the impact on SP network participation for biopharmaceutical companies with institutions, PBMs, government payers, and commercial payers?

These and other findings can be found in Health Strategies Insights by EVERSANA recently released research Impact of 340B Changes

View the Research Agenda

Visit our Specialty Pharmacies and Specialty Distributors webpage to learn more about this research.

Want access to more leading research? Click here to request more information.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.